LPCL peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

• LPCL is a polypeptide with significant potential in the field of health and medicine. It has been identified as a promising inhibitor of dipeptidyl peptidase IV (DPP-IV). This polypeptide exhibits favorable pharmacokinetic properties, suggesting its potential for effective utilization within the body.
• In vitro studies have demonstrated that LPCL shows potent inhibitory activity against DPP-IV. It has an IC50 value of 76.56 ± 3.17μM, and it functions as a competitive inhibitor. Through various interactions such as electrostatic, π-stacking, hydrogen, and hydrophobic interactions with the DPP-IV catalytic triad, LPCL can effectively bind to the enzyme. Additionally, in situ experiments have shown that LPCL can significantly reduce the DPP-IV activity in STC-1 cells to 27.40 ± 2.88%, with a relatively low IC50 value of 481.6μM. Importantly, LPCL treatment has been shown to increase the levels of active GLP-1, which is crucial for glucose homeostasis. Overall, LPCL holds great promise as a potential agent for the management of conditions related to DPP-IV activity, such as type-2 diabetes mellitus.

• Rhessa Grace Guanga Ortizo, Vishal Sharma, Mei-Ling Tsai, Parushi Nargotra, Pei-Pei Sun, Chiu Wen Chen, Cheng-Di Dong, Integrating in silico, in vitro, and in situ approaches for characterization of novel peptides from tilapia (Oreochromis niloticus) viscera hydrolysates with dipeptidyl-peptidase IV inhibitory activity, Food Bioscience, Volume 63, 2025, 105619, ISSN 2212-4292, doi: org/10.1016/j.fbio.2024.105619.

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.